Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output

JAMA

Volumn 307, Issue 9, 2012, Pages 948-955

  Dupuis Girod, Sophie ^a,b   Ginon, Isabelle ^c   Saurin, Jean Christophe ^d   Marion, Denis ^c   Guillot, Elsa ^c   Decullier, Evelyne ^b,e   Roux, Adeline ^e   Carette, Marie France ^f   Gilbert Dussardier, Brigitte ^g   Hatron, Pierre Yves ^h   Lacombe, Pascal ⁱ   Lorcerie, Bernard ^j   Rivière, Sophie ^k   Corre, Romain ^l   Giraud, Sophie ^d   Bailly, Sabine ^m   Paintaud, Gilles ⁿ   Ternant, David ⁿ   Valette, Pierre Jean ^c   Plauchu, Henri ^a,b   Faure, Frédéric ^d   more..

^a LOUIS PRADEL HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f HÔPITAL TENON   (France)

^g POITIERS UNIVERSITY HOSPITAL   (France)

^h UNIV LILLE   (France)

ⁱ HÔPITAL AMBROISE PARÉ   (France)

^j Hôpital de Dijon   (France)

^k MONTPELLIER UNIVERSITY HOSPITAL   (France)

^l PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^m INSERM   (France)

ⁿ UNIVERSITÉ DE TOURS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BEVACIZUMAB;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTERIOVENOUS MALFORMATION; ARTICLE; ASTHENIA; BLEEDING DISORDER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ECHOCARDIOGRAPHY; EPISTAXIS; FEMALE; FOLLOW UP; HEADACHE; HEART INDEX; HEART OUTPUT; HUMAN; HYPERTENSION; LIVER CIRCULATION; LIVER DISEASE; MALE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RENDU OSLER WEBER DISEASE; THROMBOEMBOLISM; TREATMENT DURATION; VOMITING;

EID: 84857865784     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.250     Document Type: Article

References (30)

1. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91(1):66-67. (Pubitemid 30127562)
2. Buscarini E, Danesino C, Olivieri C, et al. Doppler ultrasonographic grading of hepatic vascular malformations in hereditary hemorrhagic telangiectasia: results of extensive screening. Ultraschall Med. 2004; 25(5):348-355. (Pubitemid 39304438)
3. Buonamico P, Suppressa P, Lenato GM, et al. Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: echo-color-Doppler vs multislice computed tomography study. J Hepatol. 2008;48(5):811-820.
4. Buscarini E, Plauchu H, Garcia Tsao G, et al. Liverinvolvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver Int. 2006; 26(9):1040-1046. (Pubitemid 44541744)
5. Garcia-Tsao G. Liver involvement in hereditary hemorrhagic telangiectasia (HHT). J Hepatol. 2007; 46(3):499-507. (Pubitemid 46185709)
6. Faughnan ME, Granton JT, Young LH. The pulmonary vascular complications of hereditary haemorrhagic telangiectasia. Eur Respir J. 2009;33(5): 1186-1194.
7. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8(4):345-351.
8. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996;13(2):189-195.
9. Gallione CJ, Repetto GM, Legius E, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004;363(9412): 852-859. (Pubitemid 38368834)
10. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 2007;109(5): 1953-1961. (Pubitemid 46348192)
11. Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol. 2006;85(9):631-632. (Pubitemid 44283088)
12. Mitchell A, Adams LA, MacQuillan G, Tibballs J, vanden Driesen R, Delriviere L. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl. 2008;14 (2):210-213. (Pubitemid 351267278)
13. Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia.JMed Genet. 2011;48(2):73-87.
14. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 1961; 13:346-353.
15. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I, Conceptual framework and item selection. Med Care. 1992;30(6): 473-483.
16. Ternant D, Cézé N, Lecomte T, et al. An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. Ther Drug Monit. 2010;32(5): 647-652.
17. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62(5):779-786.
18. Dupuis-Girod S, Chesnais AL, Ginon I, et al. Longterm outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study. Liver Transpl. 2010;16(3):340-347.
19. Simonds J, Miller F, Mandel J, Davidson TM. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 2009;119(5):988-992.
20. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf. 2006;5(4):553-566. (Pubitemid 44468452)
21. Traina TA, Norton L, Drucker K, Singh B. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Oncologist. 2006; 11(10):1070-1071. (Pubitemid 44788397)
22. Fakih MG, Lombardo JC. Bevacizumab-induced nasal septum perforation. Oncologist. 2006;11 (1):85-86.
23. Ruiz N, Fernandez-Martos C, Romero I, et al. Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. J Clin Oncol. 2007;25(22):3376-3377. (Pubitemid 47325627)
24. Pasculli G, Resta F, Guastamacchia E, Di Gennaro L, Suppressa P, Sabbà C. Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease. Qual Life Res. 2004;13(10):1715-1723. (Pubitemid 41215251)
25. Geisthoff UW, Heckmann K, D'Amelio R, et al. Health-related quality of life in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg. 2007;136(5):726-733.
26. Khalid SK, Pershbacher J, Makan M, Barzilai B, Goodenberger D. Worsening of nose bleeding heralds high cardiac output state in hereditary hemorrhagic telangiectasia. Am J Med. 2009;122(8): 779.
27. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.NEngl J Med. 2004; 350(23):2335-2342. (Pubitemid 38702844)
28. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23 (16):3706-3712.
29. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23(16):3697-3705.
30. Lerut J, Orlando G, Adam R, et al European Liver Transplant Association. Liver transplantation for hereditary hemorrhagic telangiectasia: report of the European liver transplant registry. Ann Surg. 2006; 244(6):854-862. (Pubitemid 44808612)